Non-Small Cell Lung Cancer Stage IV

This is a clinical practice guideline for adult patients with Stage IV non-small cell lung cancer. Treatment options are discussed including the role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in first-line treatment, options for second-line therapy, and the role of palliative radiotherapy. Outcomes of interest include tumour response rate, survival (1-year, overall), time to progression, quality of life, and treatment-related adverse events.